Lung Cancer
Conditions
Keywords
Advanced NSCLC, Gefitinib, Thai patient
Brief summary
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosed as having lung cancer based on histological/cytological findings * Admitted to the hospital between January 2004 and December 2008 * Treated with gefitinib for at least 3 months
Exclusion criteria
* Involvement in the planning and/or conduct of the study * Participation in another clinical study during the last 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx. |
Secondary
| Measure | Time frame |
|---|---|
| Time to maximum response | Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx. |
| Overall survival | time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx. |
| Prevalence of EGFR & KRAS mutation from laboratory result | During Jan 2004- Dec 2008 or 5 years approx. |
Countries
Thailand
Outcome results
None listed